TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
Conditions
Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy · hATTR-PN
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Clinical Trial Site, Aurora, Colorado, United States
Clinical Trial Site, Chicago, Illinois, United States
Clinical Trial Site, Baltimore, Maryland, United States
Clinical Trial Site, Boston, Massachusetts, United States
Clinical Trial Site, Rochester, Minnesota, United States
Clinical Trial Site, New York, New York, United States
Clinical Trial Site, Chapel Hill, North Carolina, United States
Clinical Trial Site, Dallas, Texas, United States
Clinical Trial Site, Darlinghurst, Australia
Clinical Trial Site, São Paulo, Brazil
Clinical Trial Site, Égkomi, Cyprus
Clinical Trial Site, Créteil, France
Clinical Trial Site, Le Kremlin-Bicêtre, France
Clinical Trial Site, Marseille, France
Clinical Trial Site, Athens, Greece
Clinical Trial Site, Heraklion, Greece
Clinical Trial Site, Florence, Italy
Clinical Trial Site, Milan, Italy
Clinical Trial Site, Pavia, Italy
Clinical Trial Site, Suita, Japan
Clinical Trial Site, Kuala Lumpur, Malaysia
Clinical Trial Site, Porto, Portugal
Clinical Trial Site, Seoul, South Korea
Clinical Trial Site, Seoul, South Korea
Clinical Trial Site, Stockholm, Sweden
Clinical Trial Site, Umeå, Sweden
Clinical Trial Site, Taipei, Taiwan
Clinical Trial Site, Taipei, Taiwan
Clinical Trial Site, Taoyuan City, Taiwan
Study leads
Medical Director
Study Director
Alnylam Pharmaceuticals